p16与eIF4E在宫颈癌中基因改变情况的初步研究  

Preliminary Study of Genetic Change of p16 and eIF4E in Cervical Carcinoma

作　　者：郑晓娟[1,2] 胡新荣[2] 唐泽立[2] 李飞虹[2] 庞天云[3] 

机构地区：[1]江苏省昆山市第一人民医院病理科,215300 [2]广东医学院病理教研室,524023 [3]广东医学院附属医院妇产科,524001

出　　处：《实用癌症杂志》2011年第1期13-15,共3页The Practical Journal of Cancer

摘　　要：目的通过检测p16exon1,eIF4E在宫颈癌中有否扩增或丢失,确定与宫颈癌发生发展相关的分子标志。方法对41例新鲜宫颈癌标本进行显微切割和DNA提取;PCR扩增宫颈癌DNA中的靶基因p16exon1及eIF4E;运用bandscan 4.3对PCR扩增产物的电泳条带进行灰度扫描,并用软件SPSS13.0对数据进行处理,确定发生扩增或丢失的基因。结果在宫颈癌中,p16exon1、eIF4E均有不同程度的扩增,宫颈癌组织中p16exon1相对灰度的均值为0.28,正常宫颈组织相对灰度的均值为0.11;宫颈癌组织中eIF4E相对灰度的均值为1.08,正常宫颈组织相对灰度的均值为0.72。癌组织较正常组织中p16exon1、eIF4E的拷贝数明显增加,两者相比有统计学意义(P<0.05)。结论 p16exon1、eIF4E在宫颈癌中均表现为扩增,从基因的角度解释了p16蛋白在宫颈癌中表达增加的机制,提示p16和eIF4E可能可以作为宫颈癌发生发展的有用的分子标志。Objective To determine the relevant molecular markers in the development of cervical carcinoma by detecting the amplification or deletion of p16exon1 and eIF4E in cervical carcinoma.Methods Microdissection and DNA extraction were used in 41 cases of fresh cervical carcinoma specimens.p16exon1 and eIF4E were amplified through PCR method,which were target genes of cervical carcinoma.Bandscan 4.3 was used to scan the PCR product bands electrophoresed on the gels.SPSS13.0 was used to analyze the scanning data and determine the gene amplification or deletion.Results p16exon1 and eIF4E were both amplified in different extent in carcinoma.Average of relative greyscale of p16exon1 was 0.28 in cervical carcinoma,and 0.11 in normal cervical tissues.The corresponding average of eIF4E were 1.08 and 0.72,respectively.Copy numbers of p16exon1 and eIF4E were increased obviously in carcinoma tissues than normal tissues.There was significant difference between the two groups（P0.05）.Conclusion p16exon1 and eIF4E show amplification in cervical carcinoma.This result provides an explanation for the mechanism of p16 protein overexpression in cervical carcinoma from genetic angle and suggests that p16 and eIF4E may be valuable molecular markers in the development of cervical carcinoma.

关 键 词：宫颈癌 P16基因 eIF4E基因 

分 类 号：R737.33[医药卫生—肿瘤]